- Home
- SGML vs SPRY Comparison
SGML vs SPRY Comparison
Compare SGML & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGML | SPRY |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SGML | SPRY |
|---|---|---|
| Price | $14.18 | $11.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.00 | ★ $31.25 |
| AVG Volume (30 Days) | ★ 4.1M | 1.6M |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $138,959,151.00 | ★ $142,772,000.00 |
| Revenue This Year | $52.45 | N/A |
| Revenue Next Year | $22.13 | $127.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5459.66 |
| 52 Week Low | $4.25 | $6.66 |
| 52 Week High | $14.63 | $18.90 |
Technical Indicators
Market Signals| Indicator | SGML | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 66.16 | 62.10 |
| Support Level | $13.01 | $10.94 |
| Resistance Level | $14.19 | $11.99 |
| Average True Range (ATR) | 1.13 | 0.65 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 90.63 | 78.96 |
Price Performance
Historical ComparisonAbout SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.